Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dose Densified Chemoimmunotherapy With Early CNS Prophylaxis in Patients Less Than 65 Years With High Risk (aaIPI at least 2) Diffuse Large B-Cell Lymphoma.

Trial Profile

Dose Densified Chemoimmunotherapy With Early CNS Prophylaxis in Patients Less Than 65 Years With High Risk (aaIPI at least 2) Diffuse Large B-Cell Lymphoma.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 Oct 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cytarabine (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Methotrexate; Prednisone; Rituximab; Vincristine
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CHIC
  • Most Recent Events

    • 02 Mar 2020 Status changed from active, no longer recruiting to completed.
    • 06 Nov 2019 Results (n=96) of two clinical studies: a phase 2 trial; dose-dense chemoimmunotherapy (NCT01502982) and a early systemic CNS prophylaxis with high-dose methotrexate (CHIC or NCT01325194), assessing clinical feasibility and prognostic value of ctDNA in prospectively collected samples from high risk B-cell lymphoma patients, released in 61st Annual Meeting and Exposition of the American Society of Hematology
    • 04 Sep 2017 Status changed from recruiting to active, no longer recruiting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top